Skip to main content

Table 4 Comparison between groups (according to CTFPHC recommendation)

From: Changes in the outcome of prostate biopsies after preventive task force recommendation against prostate-specific antigen screening

Characteristics

Pre-recommendation

1078 Pts. (75.6%)

Post-recommendation

347 Pts. (24.3%)

P-value

Age, median [IQR]

73 [67–79]

69 [64–76]

 

Age at diagnosis, mean [range]

68.4 [40–96]

69.1 [47–91]

0.274

Age categories, n (%)

<.0001

 - < 50 years

4 (0.4%)

4 (1.1%)

 

 - 50–74 years

615 (57%)

246 (70.8%)

 

 - ≥75 years

459 (42.6%)

97 (27.9%)

 

PSA (ng/ml), median [IQR]

7.1 [5.2–11.5]

8.8 [6.4–13.4]

0.037

PSA categories, n (%)

0.011

 - ≤4

90 (8.4%)

23 (6.6%)

 

 - 4.01–10

652 (60.4%)

183 (52.7%)

 

 - 10.01–20

204 (18.9%)

89 (25.7%)

 

 - > 20

132 (12.2%)

52 (15%)

 

Prostate volume (ml3), median [IQR]

34.8 [26.4–47.1]

40.3 [29.6–56.9]

<.0001

PSA density (ng/ml/ml3), median [IQR]

0.21 [0.14–0.336

0.22 [0.12–0.38]

0.756

Gleason score

<.0001

 - Gleason 6

473 (43.9%)

93 (26.8%)

 

 - Gleason 7

327 (30.3%)

146 (42.1%)

 

 - Gleason 8–10

278 (25.8%)

108 (31.1%)

 

Clinical stage

0.035

 - T1-2a

669 (62.1%)

190 (54.7%)

 

 - 2b

252 (23.4%)

103 (29.7%)

 

 - 2c-3a

157 (14.5%)

54 (15.6%)

 

D’Amico risk classification

<.0001

 - Low

399 (37%)

78 (22.4%)

 

 - Intermediate

356 (33%)

147 (42.4%)

 

 - High

323 (30%)

122 (34.8%)